<DOC>
	<DOCNO>NCT01476774</DOCNO>
	<brief_summary>This multiple-dose , double-blind , double-dummy , active-control , parallel-group , multi-center , safety efficacy study .</brief_summary>
	<brief_title>NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain</brief_title>
	<detailed_description />
	<mesh_term>Spinal Cord Diseases</mesh_term>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Intervertebral Disc Displacement</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Males female age ≥20 , ≤80 year . Clinical diagnosis musculoskeletal pain 4 week longer nonmalignant pain etiology Visit 1 . Subject current user NSAIDS paracetamol report history insufficient therapeutic benefit musculoskeletal pain . Subjects must record 'average pain last week study institution ' score primary pain site ≥ 4 11point numerical pain rating scale . Subjects must able understands study procedure assessment , agree participate study give write informed consent . Subjects take longacting shortacting opioid analgesic formulation within last 4 week . Subjects current chronic disease ( ) past history high possibility relapse , addition musculoskeletal pain , require frequent analgesic therapy . Subjects clinically unstable respiratory disease , dysfunction biliary tract , thyroid disease , adrenal cortical insufficiency , prostatic hypertrophy require intervention renal artery stenosis . Subject past history malignant neoplasm include leukemia lymphoma . Subjects clinically unstable , active symptomatic heart disease . Subjects psychiatric disorder , uncontrolled seizure convulsive disorder . Subjects current past ( within 5 year ) history substance alcohol abuse , subject give positive result drug abuse test Screening Period . Subjects schedule therapy within study period might effect study assessment . Females pregnant , lactate possibility pregnant . Subjects value &gt; 2 time upper limit normal AST ALT total bilirubin visit 1 severe impair liver function . Subjects serum creatinine &gt; 2 mg/dL Visit 1 severe impaired renal function . Subjects serum potassium &lt; 3.5 mEq/L Visit 1 . Subjects receive hypnotic central nervous system ( CNS ) depressant . Subjects receive monoamine oxidase inhibitor ( MAOI ) within 2 week screen . Subjects history supersensitivity study drug . Known intolerance and/or lack effect tramadol . Subjects participate clinical research study within 1 month study entry . Subjects participate previously BTDS study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>